T-CURX GmbH Announces the Appointment of Thomas (Tom) Loeser as CFO and the Attendance at the JPM 41st Annual Healthcare Conference 2023 in San Francisco

T CURX logo

WÜRZBURG, Germany, December 15, 2022 / B3C newswire / -- T-CURX GmbH (T-CURX) today announces the appointment of Thomas (Tom) Loeser as the new CFO of the company and the attendance of the JPM 41st Annual Healthcare Conference 2023 in San Francisco from Jan 9-12, 2023.

Tom has served for more than 20 years as CFO of several European and US biotech companies, where he directed growth and financial strategies with particular emphasis on transatlantic company building and outreach to US capital markets.

In his last CFO position at Origenis GmbH/IZB Martinsried, Germany, Tom focused on the commercialization of its IP portfolio by the foundation of US-based Neuron23, Inc., dedicated to precision medicines for neurodegenerative diseases. Since its launch in 2019, Neuron23 has raised a total of $213 million from Kleiner Perkins, Westlake Village BioPartners, Perceptive Advisors, Softbank Vision Fund 2 and other high-profile VC/cross-over funds.

Prior to Origenis, Tom directed the financing strategy of ESBATech AG, Zurich, Switzerland. ESBATech, now a Novartis company, was recognized for its pioneering role in developing single-chain antibody fragments for ophthalmic indications by the support of a strong US-led venture capital syndicate since 2006 and the trade sale of its ophthalmology franchise to Alcon, Inc. for $589 million in 2009.

Dr. Ulf Grawunder, co-founder and CEO of T-CURX, commented on Tom’s appointment as CFO at T-CURX: “I am extremely excited that we could attract Tom Loeser to become the CFO of T-CURX. Tom is a seasoned Biotech CFO, who has led and managed many successful financings for Biotech companies, like Morphochem, ESBATech and Origenis. Tom has a wealth of experience and networks with top-tier international investors and particular US financial markets, including IPO experience. T-CURX has evolved from a German academic spin-out into a fast growing, entrepreneurial and innovative biotech firm. Backed by a small group of private investors, T-CURX is now planning to raise additional funds from top-tier European and US institutional investors to further advance T-CURX product pipeline and company development.  Based on Tom’s outstanding track record as CFO, I am extremely excited that he is joining T-CURX’ management team as a true co-pilot for me as CEO of the company, just ahead of the 41st JPM Annual Healthcare conference, where together we will jumpstart our future fundraising activities.”

Tom Loeser commented on his CFO appointment at T-CURX: “I am thrilled about joining the T-CURX management team, as it gives me the opportunity to work alongside some of the top experts within the industry and to make a significant contribution to achieving the objectives of T-CURX along its growth path. The attendance of the JPM Annual Healthcare conference will give us a jump start in 2023 and enables us to represent T-CURX to the external market, to key venture capital and other investment groups in Europe and the US.  We are very much looking forward to meeting again in person with many of our colleagues in the industry and to discuss the development and implementation of financial strategies, M&A activities as well as forward looking licensing and investment activities.”

T-CURX was co-founded by Prof. Michael Hudecek, MD, University of Würzburg, Germany, Prof. Christoph Rader, PhD, The Scripps Research Institute and University of Florida, US, and its CEO, Ulf Grawunder, PhD. The company is a German Biotech spin-out from the University of Würzburg and is pioneering next-generation CAR-T cell therapies to target various types and stages of cancer.

 

About T-CURX
T-CURX GmbH is a private German early-stage biopharmaceutical company focused on identifying, developing and commercializing next generation CAR-T cell therapies in cancer indications of high medical need. The company´s proprietary CAR-T technologies were developed in the labs of co-founder Prof. Michael Hudecek at Universitätsklinikum Würzburg and are centered around a novel Sleeping Beauty (SB) Transposon gene transfer technology, which is exclusively licensed to T-CURX. T-CURX has a development pipeline of 4 CAR-T programs, the first product is in clinical development (Ph I), the 2nd CAR-T program (novel target) is ready for clinical trial application. Additional proprietary technologies that will be leveraged in T-CURX’ developing CAR-T cell product pipeline include (i) the proprietary Matchmaker technology for optimized potency and efficacy of T-CURX’ CAR-T cell products and (ii) a proprietary safety-switch that allows to control the function of CAR-T cells after infusion into patients to improve the patient safety. 

 

Contacts

T-CURX
Ulf Grawunder, CEO
This email address is being protected from spambots. You need JavaScript enabled to view it.

For media enquiries
+49-(0)-931-250-99-712
This email address is being protected from spambots. You need JavaScript enabled to view it.

Keywords: Leadership; Organization and Administration; Receptors, Chimeric Antigen; Immunotherapy; T-Lymphocytes; Cell- and Tissue-Based Therapy; Neoplasms; Biotechnology; Germany

Published by B3C newswire

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
Ok